Skip to content
Infectious Disease



Resources for Public Health


*NOTICE of PRI​FTIN® (RIFAPENTINE) impurity issue 7-1-20*
In June 2020 Sanofi alerted the Division of Tuberculosis Elimination, other health agencies, and stakeholders worldwide about a newly detected impurity in Priftin®. The impurity, 1-cyclopentyl-4-nitrosopiperazine, is a nitrosamine and a potential carcinogen.  Read more at the links below.


Letter to Alaska providers/public health nurses​​​

Information from CDC​​

 

Alaska TB Manual



 


 


 

 

 

 

 
​​​​​